Dr. Murthy is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1155 Pressler Street
Houston, TX 77030
Education & Training
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2011 - 2014
Baylor College of MedicineResidency, Internal Medicine, 2008 - 2011
University of Alabama School of MedicineClass of 2008
University of PennyslvaniaMBE, Bioethics, 2003 - 2004
University of Alabama-BirminghamBA, Philosophy, Magna Cum Laude, 2000 - 2003
Certifications & Licensure
TX State Medical License 2010 - 2026
WA State Medical License 2023 - 2026
AZ State Medical License 2023 - 2025
GA State Medical License 2023 - 2025
LA State Medical License 2023 - 2025
MS State Medical License 2023 - 2025
OK State Medical License 2023 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
- Join now to see all
Clinical Trials
- A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Patients With HER2-Positive Advanced Solid Tumors Start of enrollment: 2020 Oct 15
Roles: Principal Investigator, Contact
- A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer Start of enrollment: 2020 Dec 01
Roles: Principal Investigator, Contact
- M7824 in Treating Patients With Stage II-III HER2 Positive Breast Cancer Start of enrollment: 2018 Aug 03
Roles: Contact, Principal Investigator
Publications & Presentations
PubMed
- 707 citationsTucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.Rashmi Krishna Murthy, Sherene Loi, Alicia Okines, Elisavet Paplomata, Erika Hamilton
The New England Journal of Medicine. 2020-02-13 - 64 citationsMK-2206 and standard neoadjuvant chemotherapy improves response in patients with human epidermal growth factor receptor 2–positive and/or hormone receptor–negative bre...A. Jo Chien, Debasish Tripathy, Kathy S. Albain, W. Fraser Symmans, Hope S. Rugo
Journal of Clinical Oncology. 2020-04-01 - 310 citationsIntracranial efficacy and survival with tucatinib plus trastuzumab and capecitabine for previously treated HER2-positive breast cancer with brain metastases in the HER...Nan Lin, Virginia F. Borges, Carey K. Anders, Rashmi Krishna Murthy, Elisavet Paplomata
Journal of Clinical Oncology. 2020-05-29
Professional Memberships
- Member
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
